Sionna Therapeutics, Inc. (NASDAQ:SION - Get Free Report) shares rose 6.8% during trading on Thursday . The company traded as high as $13.75 and last traded at $13.60. Approximately 19,493 shares traded hands during mid-day trading, a decline of 90% from the average daily volume of 186,247 shares. The stock had previously closed at $12.73.
Wall Street Analyst Weigh In
SION has been the topic of a number of recent research reports. Guggenheim initiated coverage on Sionna Therapeutics in a research report on Tuesday, March 4th. They issued a "buy" rating and a $45.00 price objective on the stock. Stifel Nicolaus assumed coverage on Sionna Therapeutics in a research report on Tuesday, March 4th. They issued a "buy" rating and a $32.00 price target on the stock. TD Cowen assumed coverage on Sionna Therapeutics in a research report on Tuesday, March 4th. They issued a "buy" rating on the stock. Finally, Wall Street Zen lowered Sionna Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd.
Get Our Latest Research Report on SION
Sionna Therapeutics Stock Down 0.8%
The company has a 50-day simple moving average of $11.74.
Sionna Therapeutics (NASDAQ:SION - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by ($0.17).
Institutional Trading of Sionna Therapeutics
Several hedge funds have recently added to or reduced their stakes in the business. TD Asset Management Inc acquired a new stake in Sionna Therapeutics during the 1st quarter worth $579,000. Goldman Sachs Group Inc. acquired a new stake in Sionna Therapeutics during the 1st quarter worth $667,000. Charles Schwab Investment Management Inc. acquired a new stake in Sionna Therapeutics during the 1st quarter worth $676,000. Woodline Partners LP acquired a new stake in Sionna Therapeutics during the 1st quarter worth $837,000. Finally, CenterBook Partners LP acquired a new stake in Sionna Therapeutics during the 1st quarter worth $1,195,000.
About Sionna Therapeutics
(
Get Free Report)
We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.
Read More
Before you consider Sionna Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sionna Therapeutics wasn't on the list.
While Sionna Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
